stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Total debt
Sanofi's total debt at the end of fiscal 2025 was $21.0B, up 21.5% from $17.3B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $20.7B. Over the past ten years it has ranged from $17.3B (fiscal 2024) to $29.1B (fiscal 2018); the current reading is higher than 64% of that period. Sanofi ranks 13th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $21.0B | 21.48% |
| FY2024 | $17.3B | (2.41%) |
| FY2023 | $17.7B | (11.52%) |
| FY2022 | $20.1B | (16.54%) |
| FY2021 | $24.0B | (6.58%) |
| FY2020 | $25.7B | (6.99%) |
| FY2019 | $27.6B | (4.99%) |
| FY2018 | $29.1B | 65.02% |
| FY2017 | $17.6B | (14.23%) |
| FY2016 | $20.6B | 11.85% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $20.7B | (18.04%) |
| Jun 2026 | $25.2B | 18.17% |
| Mar 2026 | $21.3B | 1.38% |
| Dec 2025 | $21.0B | (9.59%) |
| 21 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. compare | $62.7B |
| AMGN Amgen Inc. compare | $54.0B |
| NVS Novartis AG compare | $46.3B |
| BMY Bristol Myers Squibb Company compare | $42.9B |
| GSK GSK PLC Sponsored ADR compare | $31.9B |
| AZN AstraZeneca PLC compare | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S compare | $21.8B |
| SNY Sanofi | $20.7B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement